BioCentury | Apr 10, 2019
Distillery Therapeutics

KLRG1 inhibition to treat breast cancer, colorectal cancer and melanoma

...mAb decreased tumor volume and increased survival compared with either mAb alone. Ongoing work by Abcuro Inc....
...models. TARGET/MARKER/PATHWAY: Killer cell lectin like receptor G1 (KLRG1) LICENSING STATUS: Patent application filed by Abcuro Inc....
...Feb. 15, 2019 doi:10.18632/oncotarget.26659 CONTACT: Steven A. Greenberg, Harvard Medical School, Boston, Mass. email: sagreenberg@bwh.harvard.edu Claire Quang Abcuro Inc. Harvard...
Items per page:
1 - 1 of 1
BioCentury | Apr 10, 2019
Distillery Therapeutics

KLRG1 inhibition to treat breast cancer, colorectal cancer and melanoma

...mAb decreased tumor volume and increased survival compared with either mAb alone. Ongoing work by Abcuro Inc....
...models. TARGET/MARKER/PATHWAY: Killer cell lectin like receptor G1 (KLRG1) LICENSING STATUS: Patent application filed by Abcuro Inc....
...Feb. 15, 2019 doi:10.18632/oncotarget.26659 CONTACT: Steven A. Greenberg, Harvard Medical School, Boston, Mass. email: sagreenberg@bwh.harvard.edu Claire Quang Abcuro Inc. Harvard...
Items per page:
1 - 1 of 1